Sales & Marketing News | pharmaphorum

News

Bayer gets swift review for Kerendia in type 1 diabetes

FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

News

GHO, CBC merge to create largest healthcare investment firm

Two top healthcare investors – UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category.

News

Jury finds Takeda liable for $885m in pay-for-delay lawsuit

Takeda is on the hook for $885m damages – which could rise to $2.5bn – in a suit claiming it paid a rival to delay the launch of a generic competitor.

News

SCOTUS won't hear pharma's IRA complaints

The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.

News

AZ gets first okay for new hypertension drug baxdrostat

AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.

News

FDA hands BeOne, Taiho approvals for blood cancers

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

Bayer gets swift review for Kerendia in type 1 diabetes

GHO, CBC merge to create largest healthcare investment firm

Jury finds Takeda liable for $885m in pay-for-delay lawsuit

SCOTUS won't hear pharma's IRA complaints

AZ gets first okay for new hypertension drug baxdrostat

FDA hands BeOne, Taiho approvals for blood cancers

US puts $125m into personalised RNA therapy production

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks